Abstract
In hematopoietic stem cell transplantation (HSCT), patients receive cyclophosphamide (CPA) conditioning based on body weight, under the assumption that each individual will metabolize the drug with the same efficiency [1-3]. However, up to 20% of patients experience adverse outcomes related to CPA [4-7]. We hypothesized that due to their effects on CPA metabolism certain allelic variations of cytochrome P450 (CYP) 2B6 and 2C19 enzymes would be associated with higher regimen-related toxicity and worse outcomes in patients. We genotyped 359 patients who received allogeneic HSCT with high dose CPA conditioning. We investigated the effect of allelic variants of CYP2B6 and CYP2C19 on toxicity outcomes, nonrelapse mortality (NRM), relapse, progression free survival (PFS) and overall survival (OS). Overall, 65 (18%) patients experienced toxicity. There was no significant difference in toxicity events in patients with allelic variants of CYP2B6 or CYP2C19. However, compared to poor metabolizers, ultrarapid CYP2B6 metabolizers had worse PFS (P = 0.04). In addition, patients homozygous for CYP2C19 *2 allele had significantly worse PFS (P = 0.008) and OS (P = 0.004). Our results suggest that genotyping may help to predict survival in patients receiving high dose CPA, guide patient management and improve outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
